Impact and Enablers of Pharmacogenetic-Informed Treatment Decisions—A Longitudinal Mixed-Methods Study Exploring the Patient Perspective

Pharmacogenetic (PGx) testing is a promising approach for optimizing drug therapies. However, there is limited knowledge regarding its real-world utilization and long-term impact in clinical practice. This study assessed how often PGx information informs treatment decisions and evaluated patients’ p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacy Jg. 13; H. 1; S. 14
Hauptverfasser: Bollinger, Anna, Semedo Fortes, Melissa, Meyer zu Schwabedissen, Henriette E., Hersberger, Kurt E., Stäuble, Céline K., Allemann, Samuel S.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI AG 31.01.2025
MDPI
Schlagworte:
Clinical medicine
Data analysis
Drug dosages
Drug therapy
implementation
Interviews
Longitudinal studies
medication changes
Mixed methods research
patient perspective
Patients
PGx
Questionnaires
PGx
medication changes
patient perspective
implementation
ISSN:2226-4787, 2226-4787
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pharmacogenetic (PGx) testing is a promising approach for optimizing drug therapies. However, there is limited knowledge regarding its real-world utilization and long-term impact in clinical practice. This study assessed how often PGx information informs treatment decisions and evaluated patients’ perspectives on its use and non-use, identifying enablers for PGx implementation. A mixed-methods study was conducted with 24 patients with a median of 1 year after PGx testing. Medication and health-related data were collected at enrollment and at the follow-up 1 year later using a semi-structured questionnaire. At the follow-up, 62 medication changes were identified in 18 patients. A median of four medication changes per patient were initiated mainly by medical specialists (58%). PGx information was considered for 15 patients in 39 medication changes (63%). Patient-reported factors contributing to the non-use of PGx information included a lack of knowledge and interest among healthcare professionals (HCPs), structural and administrative barriers, and an over-reliance on patient advocacy. Potential enablers should address targeted PGx education, interprofessional collaboration, awareness among policymakers, and concise recommendations focused on PGx-actionable drugs from testing providers. By implementing these interdependent enablers, PGx can evolve into a long-term, clinically integrated cornerstone of individualized pharmacotherapy.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2226-4787
2226-4787
DOI:10.3390/pharmacy13010014